Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 4;8(14):23862-23870.
doi: 10.18632/oncotarget.13317.

Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer

Wei Wei  1 , Ning Li  1 , Yangchun Sun  1 , Bin Li  1 , Lily Xu  2 , Lingying Wu  1
Affiliations

Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer

Wei Wei et al. Oncotarget. .

Abstract

Some subsets of early stage ovarian cancer patients experience more recurrences than others. Studies on prognostics factors gave conflicting results. We investigated consecutive 221 patients with stage I/II ovarian cancer at our institution from 1999 to 2010. Univariate and multivariate analysis of progression free survival (PFS) and overall survival (OS) were performed. After a median follow-up of 79 months, the 5-year/10-year PFS and 5-year/10-year OS were 78% /76% and 90% /87% respectively. Multivariate analysis revealed that stage as the most prominent independent prognostic factor in terms of PFS (stage I vs stage IIA vs stage IIB, Hazard Ratio (HR): 1 vs 4 vs 6.1, P < 0.05) and OS (stage I vs stage II, HR: 1 vs 2.1, P < 0.05). Peritoneal biopsy reduced the risk of recurrence by 29% (95% CI: 0.15-0.58, P < 0.05). Ascites (HR = 2.8, 95% CI: 1.2-6.6, P < 0.05) and not the first-line chemotherapy (HR = 2.6, 95% CI: 1.1-6.5, P < 0.05) contributed to decreased OS. Overall, early-stage ovarian cancer had a favorable outcome, stage was the most powerful prognostic factor.

Keywords: early-stage; ovarian cancer; prognosis; recurrence; survival.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

All Authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Kaplan-Meier estimated PFS and OS stratified by FIGO stage
A. Progression free survival calculated by log-rank test. (stage IA/B vs stage IC vs stage IIA vs stage IIB, P < 0.01; stage IA/B vs stage IC, P = 0.091; stage IIA vs stage IIB, P = 0.43) and B. Overall survival calculated by log-rank test. (stage IA/B vs stage IC vs stage IIA vs stage IIB, P < 0.01; stage IA/B vs stage IC, P = 0.16; stage IIA vs stage IIB, P = 0.572).
Figure 2
Figure 2. Kaplan-Meier estimated PFS and OS stratified by residual mass
A. Progression free survival calculated by log-rank test. (without residual mass vs with residual mass, P < 0.01) and B. Overall survival calculated by log-rank test. (without residual mass vs with residual mass, P < 0.01).
Figure 3
Figure 3. Kaplan-Meier estimated PFS and OS stratified by ascites
A. Progression free survival calculated by log-rank test. (ascites absent vs ascites present, P = 0.02) and B. Overall survival calculated by log-rank test. (without residual mass vs with residual mass, P < 0.01).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65:87–108. - PubMed
    1. Chen WQ, Zheng RS, Peter DB, Zhang SW, Zeng HG, Freddie B, Ahmedin J Yu XQ, He J. Cancer statistics in China, 2015. CA: a cancer journal for clinicians. 2015;66:115–132. - PubMed
    1. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obste. 2014;1:1–5. - PubMed
    1. Harrison ML, Cameson C, Gore ME. Mucinous ovarian cancer. Int J Gynecol Obste. 2008;2:209–214. - PubMed
    1. Fleming GF, Seidman J, Lengyel E. Principles and Practice of Gynecologic Oncology. 6th. Philadelphia: Lippincott Williams & Wilkins; 2013.